Considerations and caveats in anti-virulence drug development.

[1]  R. Platt,et al.  Surgical Site Infections , 2016, Medical care.

[2]  Sang-Bum Hong,et al.  Sepsis and Acute Respiratory Distress Syndrome: Recent Update , 2016, Tuberculosis and respiratory diseases.

[3]  S. Nathan,et al.  Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy , 2016, Toxins.

[4]  R. Hartmann,et al.  Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections. , 2016, Journal of medicinal chemistry.

[5]  David W Bates,et al.  Integrating Predictive Analytics Into High-Value Care: The Dawn of Precision Delivery. , 2016, JAMA.

[6]  I. Henderson,et al.  Alternatives to antibiotics-a pipeline portfolio review. , 2016, The Lancet. Infectious diseases.

[7]  H. Xiang,et al.  The therapeutic effect of chlorogenic acid against Staphylococcus aureus infection through sortase A inhibition , 2015, Front. Microbiol..

[8]  L. Popa,et al.  Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. , 2015, Current topics in medicinal chemistry.

[9]  Yue Zheng,et al.  Agents that inhibit bacterial biofilm formation. , 2015, Future medicinal chemistry.

[10]  Alexander A. Morgan,et al.  Prediction of multiple infections after severe burn trauma: a prospective cohort study. , 2015, Annals of surgery.

[11]  X. Zhou,et al.  Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self‐assembly of α‐hemolysin , 2015, Journal of applied microbiology.

[12]  Yonatan H. Grad,et al.  Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens , 2015, Microbiology and Molecular Reviews.

[13]  R. Hartmann,et al.  Catechol-based substrates of chalcone synthase as a scaffold for novel inhibitors of PqsD. , 2015, European journal of medicinal chemistry.

[14]  Wai-Fong Yin,et al.  Non-antibiotic quorum sensing inhibitors acting against N-acyl homoserine lactone synthase as druggable target , 2014, Scientific Reports.

[15]  M. Fröhlich,et al.  Evaluation of the Toxicity of 5-Aryl-2-Aminoimidazole-Based Biofilm Inhibitors against Eukaryotic Cell Lines, Bone Cells and the Nematode Caenorhabditis elegans , 2014, Molecules.

[16]  Jasmine Lee,et al.  The hierarchy quorum sensing network in Pseudomonas aeruginosa , 2014, Protein & Cell.

[17]  S. de Bentzmann,et al.  Characterization of a novel two-partner secretion system implicated in the virulence of Pseudomonas aeruginosa. , 2014, Microbiology.

[18]  H. Blackwell,et al.  Competition Studies Confirm Two Major Barriers That Can Preclude the Spread of Resistance to Quorum-Sensing Inhibitors in Bacteria , 2014, ACS chemical biology.

[19]  A. Tzika,et al.  Identification of Anti-virulence Compounds That Disrupt Quorum-Sensing Regulated Acute and Persistent Pathogenicity , 2014, PLoS pathogens.

[20]  Jintae Lee,et al.  Anti-biofilm, anti-hemolysis, and anti-virulence activities of black pepper, cananga, myrrh oils, and nerolidol against Staphylococcus aureus , 2014, Applied Microbiology and Biotechnology.

[21]  B. Sellman,et al.  A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models , 2014, Antimicrobial Agents and Chemotherapy.

[22]  Stephen P. Diggle,et al.  Targeting virulence: can we make evolution-proof drugs? , 2014, Nature Reviews Microbiology.

[23]  W. Chan,et al.  Targeting Staphylococcus aureus Quorum Sensing with Nonpeptidic Small Molecule Inhibitors , 2014, Journal of medicinal chemistry.

[24]  Sam P. Brown,et al.  Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment , 2014, Evolution, medicine, and public health.

[25]  Ori J. Lieberman,et al.  High-throughput screening using the differential radial capillary action of ligand assay identifies ebselen as an inhibitor of diguanylate cyclases. , 2014, ACS chemical biology.

[26]  Richard D. Smith,et al.  Activated ClpP kills persisters and eradicates a chronic biofilm infection , 2013, Nature.

[27]  Knut Drescher,et al.  A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation , 2013, Proceedings of the National Academy of Sciences.

[28]  T. Wood,et al.  Resistance to Quorum-Quenching Compounds , 2013, Applied and Environmental Microbiology.

[29]  J. Engel,et al.  Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[30]  P. Williams,et al.  Structural Basis for Native Agonist and Synthetic Inhibitor Recognition by the Pseudomonas aeruginosa Quorum Sensing Regulator PqsR (MvfR) , 2013, PLoS pathogens.

[31]  Michael Y. Galperin,et al.  Cyclic di-GMP: the First 25 Years of a Universal Bacterial Second Messenger , 2013, Microbiology and Molecular Reviews.

[32]  Brendan F Gilmore,et al.  Clinical relevance of the ESKAPE pathogens , 2013, Expert review of anti-infective therapy.

[33]  R. Tompkins,et al.  The Quorum Sensing Volatile Molecule 2-Amino Acetophenon Modulates Host Immune Responses in a Manner that Promotes Life with Unwanted Guests , 2012, PLoS pathogens.

[34]  Michael P. Storz,et al.  Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors. , 2012, Journal of the American Chemical Society.

[35]  A. Mebazaa,et al.  Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial* , 2012, Critical care medicine.

[36]  R. Morona,et al.  Chemical Inhibition of Bacterial Protein Tyrosine Phosphatase Suppresses Capsule Production , 2012, PloS one.

[37]  J. Colmer-Hamood,et al.  Garlic ointment inhibits biofilm formation by bacterial pathogens from burn wounds. , 2012, Journal of medical microbiology.

[38]  Ozlem Sandikci,et al.  [Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients]. , 2012, Mikrobiyoloji Bulteni.

[39]  L. Rahme,et al.  Honey’s Ability to Counter Bacterial Infections Arises from Both Bactericidal Compounds and QS Inhibition , 2012, Front. Microbio..

[40]  Martin Schuster,et al.  The Sociomicrobiology of Antivirulence Drug Resistance: a Proof of Concept , 2011, mBio.

[41]  L. Garcia,et al.  Quorum quenching quandary: resistance to antivirulence compounds , 2011, The ISME Journal.

[42]  L. Rahme,et al.  A Quorum Sensing Regulated Small Volatile Molecule Reduces Acute Virulence and Promotes Chronic Infection Phenotypes , 2011, PLoS pathogens.

[43]  Richard A. Moore,et al.  Development and Application of a Cellular, Gain-of-Signal, Bioluminescent Reporter Screen for Inhibitors of Type II Secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei , 2011, Journal of biomolecular screening.

[44]  R. Hartmann,et al.  Biosynthesis of 2‐Alkyl‐4(1H)‐Quinolones in Pseudomonas aeruginosa: Potential for Therapeutic Interference with Pathogenicity , 2011, Chembiochem : a European journal of chemical biology.

[45]  Haihua Feng,et al.  Menthol diminishes Staphylococcus aureus virulence-associated extracellular proteins expression , 2011, Applied Microbiology and Biotechnology.

[46]  H. Ceri,et al.  Needed, new paradigms in antibiotic development , 2010, Expert opinion on pharmacotherapy.

[47]  A. Hauser.  The type III secretion system of Pseudomonas aeruginosa: infection by injection , 2009, Nature Reviews Microbiology.

[48]  V. Nizet,et al.  Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. , 2009, Journal of medicinal chemistry.

[49]  C. Melander,et al.  Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. , 2009, Organic & biomolecular chemistry.

[50]  D. Mack,et al.  Inhalation with Fucose and Galactose for Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients , 2008, International journal of medical sciences.

[51]  Samuel I. Miller,et al.  An inhibitor of gram-negative bacterial virulence protein secretion. , 2008, Cell host & microbe.

[52]  C. Melander,et al.  Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing bacterial biofilms across order, class, and phylum. , 2008, Angewandte Chemie.

[53]  H. Boucher,et al.  Epidemiology of methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  Atlanta,et al.  Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States , 2007 .

[55]  R. Tompkins,et al.  Inhibitors of Pathogen Intercellular Signals as Selective Anti-Infective Compounds , 2007, PLoS pathogens.

[56]  P. Cosson,et al.  Inhibitors of bacterial virulence identified in a surrogate host model , 2007, Cellular microbiology.

[57]  T. Liljefors,et al.  The LuxR receptor: the sites of interaction with quorum-sensing signals and inhibitors. , 2005, Microbiology.

[58]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[59]  M. Oh,et al.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  S. Kjelleberg,et al.  Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors , 2003, The EMBO journal.

[61]  Michael S. Gilmore,et al.  Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis , 2002, Nature.

[62]  R. Irvin,et al.  Interaction between the pili of Pseudomonas aeruginosa PAK and its carbohydrate receptor β-D-GalNAc(1->4) β-D-Gal analogs , 1998 .

[63]  H. Hang,et al.  Small molecules aimed at type III secretion systems to inhibit bacterial virulence. , 2013, MedChemComm.

[64]  M. Bottomley,et al.  Covalent inhibition of bacterial quorum sensing. , 2009, Journal of the American Chemical Society.

[65]  N. Siafakas,et al.  Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[66]  V. Nizet,et al.  A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. , 2008, Science.

[67]  R. Irvin,et al.  Interaction between the pili of Pseudomonas aeruginosa PAK and its carbohydrate receptor beta-D-GalNAc(1-->4)beta-D-Gal analogs. , 1998, Canadian Journal of Microbiology (print).